Immune response against therapeutic factor VIII in hemophilia A patients—A survey of probable risk factors

Dasgupta, Suryasarathi and Navarrete, Ana-Maria and Delignat, Sandrine and Wootla, Bharath and Andre, Sebastien and Nagaraja, Valakunja and Lacroix-Desmazes, Sebastien and Kaveri, Srinivas V (2007) Immune response against therapeutic factor VIII in hemophilia A patients—A survey of probable risk factors. In: Immunology Letters, 110 (1). pp. 23-28.

PDF Immune_response.pdf Restricted to Registered users only Download (374kB) | Request a copy

Abstract

A number of diseases are treated by passive administration of human proteins. Human coagulation factor VIII (FVIII) is one such protein which is adminsitered to hemophilia A patients in order to manage and treat hemorrhagic incidences. This mode of therapy suffers from the side effect of generating anti-FVIII antibodies (inhibitors) which neutralizes the function of the infused FVIII. At a time when efficient viral screening procedures are at place, development of inhibitors poses the greatest threat to such a therapy. Various predisposing factors, both patient and product-related, are responsible for the development of inhibitory antibodies. A proper understanding of these “risk-factors” would eventually help to better design therapeutic regimen to tackle hemophilia A.

Item Type:	Journal Article
Publication:	Immunology Letters
Publisher:	Elsevier
Additional Information:	Copyright of this article belongs to Elsevier.
Keywords:	Factor VIII;Hemophilia;Inhibitors;Risk factors
Department/Centre:	Division of Biological Sciences > Microbiology & Cell Biology
Date Deposited:	15 Oct 2007
Last Modified:	19 Sep 2010 04:39
URI:	http://eprints.iisc.ac.in/id/eprint/11785

Actions (login required)

View Item